Biogen News Releases and Company Statements

Media Contacts
US Media Relations
Europe Media Relations
Japan Media Relations
June 10, 2024
Biogen Announces Webcast of Annual Meeting of Stockholders
June 9, 2024
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
June 3, 2024
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
May 30, 2024
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 30, 2024
Biogen to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 26, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
May 23, 2024
Biogen to Participate in the Jefferies Global Healthcare Conference
May 22, 2024
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 16, 2024
Statement: Biogen Shares Update on Angelman Syndrome Program
May 16, 2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon